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Abstract
Schizophrenia is a neurodevelopmental disorder with high heritability. Several lines of evidence indicate that the PRODH
gene may be related to the disorder. Therefore, our study investigates the effects of 12 polymorphisms of PRODH on
schizophrenia and its phenotypes. To further evaluate the roles of the associated variants in the disorder, we have
conducted magnetic resonance imaging (MRI) scans to assess cortical volumes and thicknesses. A total of 192 patients were
evaluated using the Structured Clinical Interview for DSM-IV (SCID), Positive and Negative Syndrome Scale (PANSS), Calgary
Depression Scale, Global Assessment of Functioning (GAF) and Clinical Global Impression (CGI) instruments. The study
included 179 controls paired by age and gender. The samples were genotyped using the real-time polymerase chain
reaction (PCR), restriction fragment length polymorphism (RFLP)-PCR and Sanger sequencing methods. A sample of 138
patients and 34 healthy controls underwent MRI scans. One polymorphism was associated with schizophrenia (rs2904552),
with the G-allele more frequent in patients than in controls. This polymorphism is likely functional, as predicted by PolyPhen
and SIFT, but it was not associated with brain morphology in our study. In summary, we report a functional PRODH variant
associated with schizophrenia that may have a neurochemical impact, altering brain function, but is not responsible for the
cortical reductions found in the disorder.
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Introduction
Schizophrenia is currently considered to be a neurodevelop-
mental disease that arises from a complex phase-specific interac-
tion of genetic and environmental factors [1–3]. The prevalence of
schizophrenia in the general population is estimated to be 0.3%–
1.6% [4,5]. The high heritability (,64%–83%) of schizophrenia
[6,7] may be due to a combination of multiple common alleles,
each one with a small to moderate effect, and some rare alleles
with much larger effect sizes [8].
One of the strongest known genetic risk factors for schizophre-
nia is the 22q11 deletion [9]. Up to one-third of patients with
22q11 deletion syndrome (22q11DS), also known as DiGeorge or
velocardiofacial syndrome, develop schizophrenia or schizoaffec-
tive disorder [10]. Moreover, while the prevalence of the
chromosome 22q11 deletion in the general population is one in
4000 individuals, its frequency is estimated to be approximately
1% in adult patients with schizophrenia [11–14]. Therefore, the
22q11DS deletion has been suggested as a genetic subtype of
schizophrenia, and the genes located in this region might therefore
contribute to susceptibility to the disease.
One of the genes commonly deleted in 22q11DS is the proline
dehydrogenase (PRODH) gene, which encodes the proline
dehydrogenase enzyme that catalyzes the first step in proline
catabolism [15]. The PRODH gene, consisting of 14 coding exons
and located in a low copy repeat sequence, is widely expressed in
the brain and in other tissues [16,17]. The resulting enzyme, also
known as proline oxidase (POX), is a mitochondrial tumor
suppressor [18] that inhibits proliferation and induces apoptosis
[19]. High proline concentrations appear to activate NMDA and
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AMPA receptors and may therefore act as a neuromodulator [20–
22]. Proline is also a precursor of the neurotransmitter glutamate
[23], which seems to be involved in schizophrenia pathophysiol-
ogy. Moreover, whereas high levels of plasma proline are found on
a relatively common basis in patients with 22q11DS [24,25], some
evidence suggests that hyperprolinemia may lead to neurocogni-
tive dysfunction in animal models [26,27] and may be involved in
the cognitive and psychiatric features of 22q11DS [25].
Patients with 22q11.2 deletion syndrome present abnormalities
in brain structure, such as a global brain volumetric reduction that
includes several cortical regions, the cerebellum and the hippo-
campus [28]. Similarly, patients with schizophrenia consistently
present brain volumetric reductions compared to healthy controls,
specifically due to grey matter reductions of the anterior cingulate,
frontal (particularly medial and inferior) and temporal lobes,
hippocampus/amygdala, thalamus, and insula that may be
magnified over time [29]. A widespread cortical thickness
reduction has also been found in the frontal, parietal, temporal
and occipital regions of patients with schizophrenia [30].
Only two previous studies have investigated the role of PRODH
in brain volume. The first, employing a sample of 92 healthy
controls, observed a decrease in the striatal grey matter volumes of
carriers of the functional risk haplotype, which contains the
rs4819756, rs2870983, and rs450046 minor alleles (haplotype:
GCC) [31]. The other study investigated two other PRODH single
nucleotide polymorphisms (SNPs - rs2008720 and rs372055) with
respect to brain anatomy in a sample of 51 patients with
schizophrenia. While no association was found for rs2008720,
significant differences in grey matter (GM) and total brain volume
were revealed for rs372055, with C carriers showing increased
total GM and total brain volume in comparison with patients
carrying the TT genotype [32].
However, the associations of other important functional
PRODH SNPs with brain morphology have not been investigated,
and neither previous study investigated the different roles of these
polymorphisms in both normal and pathological conditions. In the
present study, we aimed to associate 12 PRODH polymorphisms,
and especially functional variants, with schizophrenia and other
clinical variables such as treatment resistance, age of onset, and
positive and negative symptoms. To further understand the
impacts of the studied polymorphisms, we conducted MRI scans
in a subsample of patients.
Materials and Methods
Ethics Statement
This study was approved by the Research Ethics Committee of
UNIFESP [CEP No. 1737/06]. Written informed consent was
obtained from all recruited participants or their caregivers, and the
clinical and laboratory investigations were strictly conducted
according to the principles expressed in the Declaration of
Helsinki. All invited subjects agreed to enroll in this study. If the
patients were within a stable period according to their clinical
features and could understand the consent forms, they double-
signed the documents themselves. The next of kin, caretakers or
guardians consented on the behalf of those participants whose
capacity to consent was compromised.
Subjects
A total of 192 chronically medicated outpatients were recruited
from the Schizophrenia Program (PROESQ) at the Universidade
Federal de Sa˜o Paulo (UNIFESP). The diagnosis of schizophrenia
was established according to the criteria of the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV),
using the Structured Clinical Interview of the DSM-IV (SCID).
Other clinical variables were assessed using the Positive and
Negative Syndrome Scale (PANSS); Calgary Depression Scale
[33]; Global Assessment of Functioning (GAF); and Clinical
Global Impression (CGI) [34] instruments. All available informa-
tion, including medical records, were used to assess remission,
which was defined by mild severity (score of 3 or lower) in eight
items of the PANSS maintained for the 6 months before the
assessment, as previously proposed [35]. The illness duration was
directly assessed with the patient, and when in doubt, a companion
or informant was questioned and/or the information was
recovered from the available clinical records. Symptom clusters
(Negative, Positive, Disorganization, Excited and Anxiety/De-
pression) were classified according to the PANSS ratings [35].
Treatment-resistant (TR) status was defined, in accordance with
the International Psychopharmacological Criteria (IPAP) [www.
ipap.org], as a failure to respond to 4- to 6-week trials of
monotherapy with two different antipsychotics at adequate doses
(equivalent to 5 mg of risperidone or 400 mg of chlorpromazine).
A 1.5 Mb microdeletion in 22q11.2 was detected in one patient
with schizophrenia using multiplex ligation-dependent probe
amplification [11]. Therefore, this subject was excluded from the
analyses, as this deletion could be a confounding genotype factor.
A total of 179 healthy subjects with no family history of severe
psychiatric illness were recruited by UNIFESP. These subjects
were also investigated using a modified version of SCID screening
to exclude any with a previous illness episode with psychotic
features or a family history of similar diseases.
Considering that the Brazilian population is admixed, the
population structure was verified for a sample of our study
population (Table 1).
DNA Isolation and Population Structure Analysis
Whole blood was collected into EDTA tubes and genomic DNA
isolation was performed using the Gentra Puregene Kit (Qiagen,
Maryland, USA) according to the manufacturer’s protocol.
The population genetic ancestry structure was assessed by a
panel of 48 ancestry-informative insertion-deletion polymor-
phisms, previously described and validated in the Brazilian
population [36], analyzed in three multiplex PCR assays followed
by capillary electrophoresis.
PRODH Genotyping
A total of 12 PRODH SNPs were interrogated (Figure 1) by real-
time polymerase chain reaction (PCR), restriction fragment length
polymorphism (RFLP)-PCR and sequencing techniques. For real-
time PCR, three SNPs (rs4819756 in exon 5, rs450046 in exon 14
and rs372055 in exon 15) were genotyped using commercially
available predesigned TaqManH probes and primers (Applied
Biosystems, Foster City, USA), as described by the manufacturer.
One polymorphism (L289M in exon 8) was investigated by the
RFLP-PCR technique using the BsaBI enzyme and the following
PCR primers: 59-TGGTGGGGAGGAGGAGGTCA-39 (for-
ward) and 59-CAGCCAGGACTGGGAGACGT-39 (reverse).
The other eight SNPs in exon 12 (rs16983466, rs2238731,
rs2904552, rs2904551, rs3970559, rs2238730, rs2870984 and
rs2870983) were investigated using Sanger sequencing. The PCR
primers were as follow: 5’-TCCCCACTGCCATTGCTCCT-39
(forward) and 59-CCTGCCCTGAGAAGACAGAG-39 (reverse).
The PCR conditions are available upon request.
Genetic Analysis
The characteristics of the study population are described in
Table 1. First, the Hardy-Weinberg equilibrium was verified for all
PRODH Variants in Schizophrenia
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SNPs using the chi-square test. Logistic regression was then
performed to associate each genotype with the diagnosis of
schizophrenia, using age as a covariate. The Bonferroni correction
for multiple comparisons was performed. The linkage disequilib-
rium and haplotypes were assessed using Haploview [37]. The
associations between the haplotypes and the disease were
investigated using the chi-square test.
Statistical analyses were performed using the Statistical Package
for the Social Sciences (SPSS version 15.0), and the level of
significance was set at 0.05.
In silico Analysis
For the SNPs associated with schizophrenia, we tested the
predictive values using SIFT (http://sift.jcvi.org/) and PolyPhen
(http://genetics.bwh.harvard.edu/pph/) and analyzed the amino
acid conservation using the UCSC genome browser (http://
genome.ucsc.edu). Both SIFT and PolyPhen predict whether an
amino acid substitution affects protein function. SIFT prediction is
based on the degree of conservation of amino acid residues in
sequence alignments [38], while PolyPhen uses straightforward
physical and comparative considerations [39].
Table 1. Descriptive characteristics of the study population.
Variables SCZ patients Controls p-values
N Frequency/values N Frequency/values
Gender 192 179 0.375
Male 131 68.2% 114 63.7%
Female 61 31.8% 65 36.3%
Age (years) 192 35.68610.38 178 38.29612.88 0.033
Ancestry
European 164 0.6760.22 137 0.6960.19 0.278
African 164 0.1860.17 137 0.1760.16 0.454
Native-American 164 0.1560.14 137 0.1460.11 0.426
Age at onset 176 23.3267.24
Treatment response 145
TR 71 50.3%
NTR 70 49.7%
GAF 144 50.00613.29
CGI 144 3.8461.07
PANSS - Negative symptoms 144 25.2468.04
PANSS – Positive symptoms 143 16.8865.98
PANSS - Excited 143 7.3162.51
PANSS – Anxiety/depression 144 9.2163.23
Calgary 144 2.7963.87
TR: Treatment resistant; NTR: Non-treatment resistant; GAF: Global Assessment of Functioning; CGI: Clinical Global Impression; PANSS: Positive and Negative Syndrome
Scale; N: sample size; SCZ: schizophrenia.
doi:10.1371/journal.pone.0087686.t001
Figure 1. Diagram of the PRODH gene, representing the variants investigated in this study and their locations.
doi:10.1371/journal.pone.0087686.g001
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Imaging Acquisition
Brain MRIs were obtained from 138 subjects with schizophre-
nia (93 men, age = 35.21610.21; 45 women, age = 39.27611.24)
and 34 healthy controls (23 men, age = 32.4367.33; 11 women,
age = 38.73615.78) using a 1.5T scanner [Magnetom Sonata
(Maestro Class) Siemens AG, Medical Solutions, Erlangen,
Germany] with an eight-channel head coil. A series of exploratory
sagittal images (nine to eleven slices of 5 mm with 1 mm spacing)
was performed to evaluate the image quality and the positioning of
the head of each subject. T1 images were acquired sequentially
using a pulse sequence (SPGR) with the following parameters: TR
=2000 ms, TE = 3.42 ms, matrix size = 256 x 256, FOV
=245 mm, flip angle = 15 degrees, NEX =1, 1.0 mm slice
thickness with no gaps, yielding 192 slices.
Imaging Preprocessing – FreeSurfer
The MRI scans were analyzed using the FreeSurfer software
package (version 5.0 http://surfer.nmr.mgh.harvard.edu) based
on established processing steps (recon-all pipeline). The cortical
volumes and thickness information of the brain regions were
estimated using the automated parcellation of the Desikan-
Killiany Atlas [40] and exported to SPSS for further analysis.
Imaging Group Analysis
First, a general linear model (GLM) was used to assess the
association of each cortical and subcortical volume and thickness
with schizophrenia. Then, all measures were inserted as dependent
variables, and each SNP, schizophrenia diagnosis and the
interaction between them were included as fixed factors. The
total intracranial volume (TIV), gender and age were included as
covariates. Statistical significance was set a priori at a two-tailed
alpha of 0.05.
Results
Association between PRODH Variants and Schizophrenia
The genotype and allele frequencies for each variant are
represented in Table S1. The genotype distributions did not
deviate from those predicted by the Hardy-Weinberg equilibrium
in both the case and control groups (p.0.05) for all variants,
except for rs4819756 (controls: x2 = 4.38, df = 1, p = 0.036; cases:
x2 = 9.70, df = 1, p = 0.002) and rs450046 (cases: x2 = 4.20, df
= 1, p = 0.040).
Regarding allele comparisons, one polymorphism was associat-
ed with schizophrenia [rs2904552 (G-allele): p = 0.002, OR
=2.65, 95%CI = 1.45–4.86] after Bonferroni correction (adjusted
p-value = 0.024). Comparing the genotypes of rs2904552, we
found that the GG-genotype carriers were at greater risk for a
schizophrenia diagnosis in comparison to the AG-genotype
carriers (adjusted p-value = 0.048, OR =2.61, 95%CI = 1.36–
5.03). Comparing the GG homozygotes to the A-allele carriers
(grouping GA and AA genotype carriers), a stronger association
was found (adjusted p-values = 0.024; OR =2.77; 95%CI
= 1.45–5.30). In all these analyses, the power was .80% as
determined using G*Power 3.1.6.
For the haplotype analyses, only polymorphisms in Hardy-
Weinberg equilibrium and with a minor allele frequency .5%
were included (rs16983466, rs2238731, rs2904552, rs2870983 and
rs372055). The results of the linkage disequilibrium test are
described in Figure S1. One haplotype block composed of three
variants, and five composed of two variants, were analyzed (Table
S2). Concerning the haplotype composed by three variants, a
significant association was detected between the A/G/C haplo-
type (rs2904552/rs2238731/rs16983466) and schizophrenia (p
= 0.001). Analyzing the combinations of two variants, only those
haplotypes constructed with rs2904552 SNP remained significant
(p,0.05– Table S2).
Association between PRODH Variants and Schizophrenia
Phenotypes
We analyzed the association of age at onset, TR, GAF, CGI,
Calgary, Negative, Positive, Disorganized, Excited and Anxiety/
Depression clusters with each PRODH polymorphism, but no
significant associations were detected.
In silico Analysis
To predict the likely pathogenicity of rs2904552, we conducted
an in silico analysis. This SNP seems to have a functional role, as it
was classified as ‘‘probably damaging,’’ with a score of 0.996, using
PolyPhen and as ‘‘damaging,’’ with a score of 0.04, using SIFT.
Data were also available for five orthologous species (three
mammals, one frog and one fish), and the residues showed
evolutionary conservation in all these organisms. Furthermore, this
variation was reported in a previous study to decrease the enzyme
activity [41].
Association between MRI and Schizophrenia
For the cortical and subcortical volumes, 21 regions were
associated with schizophrenia after Bonferroni correction and are
described in Table S3. In terms of cortical thickness, seven regions
differed between the cases and controls (Table S4).
Association between PRODH Variants and MRI
In the comparison of all PRODH genotypes with all brain
volumes and cortical thicknesses, only one association remained
significant after Bonferroni correction: the interaction between
rs2238731 (V427M) and schizophrenia was associated with right
pars opercularis volume (p = 0.00020; effect size = 0.081; power
= 0.965). Controls carrying the GA genotype had an increased
volume (6261.506144.95 mm3) in this region compared to
carriers of the GG genotype (4193.376628.09 mm3). However,
in schizophrenia patients, GA genotype carriers had a smaller
volume (3796.686527.12 mm3) than did GG carriers
(3993.416733.26 mm3).
Discussion
In this study, one PRODH variant (rs2904552 or R431H) and its
haplotypes were associated with schizophrenia, with the GG
genotype present at a higher frequency among patients than
among healthy controls. To further understand the role of this
SNP, we investigated its role in brain volumes and cortical
thicknesses.
PRODH Polymorphisms and Schizophrenia
Among the 12 investigated SNPs, 10 had been previously
associated with schizophrenia (rs372055, rs450046), hyperprolin-
emia (L289M, rs2870983, rs4819756, rs2904552, rs2870984) or
both (rs2904551, rs2238731, rs3970559); two SNPs had not been
previously investigated (rs16983466, rs2238730).
Different lines of evidence suggest an important role for PRODH
in schizophrenia: 1) it is located at 22q11.2, the deletion of which
is one of the strongest genetic risk factors for schizophrenia; 2)
PRODH deletion missense mutations have been described in
patients with schizophrenia [41,42]; 3) an association between
schizoaffective disorders and moderate hyperprolinemia was
previously been detected [43]; 4) it is widely expressed in the
PRODH Variants in Schizophrenia
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brain; 5) mice with PRODH deficiency show elevated plasma and
brain proline levels, locally decreased glutamate and c-aminobu-
tyric acid (GABA) levels and a deficit in sensorimotor gating
[17,44]; 6) the PRODH enzyme is rate limiting in the conversion
of proline to glutamate [41], which is important for signal
transduction between neurons and for synaptic plasticity [45] and
seems to be deregulated in schizophrenia [46].
Indeed, a recent metabolomics study reported abnormalities
related to proline metabolism in schizophrenia [47]. Furthermore,
Savio et al. (2012) reported that long-term exposure to proline
induced behavioral changes in adult zebrafish that were reversed
by the acute administration of atypical antipsychotics [48]. In this
vein, several studies have investigated peripheral proline levels as a
risk factor for schizophrenia (reporting no association) [49,50] or
the positive associations between hyperprolinemia and schizoaf-
fective disorder [43] and schizophrenia in women [51]. Despite
these mixed findings, the data still support a functional role for
PRODH variants and hyperprolinemia in the pathophysiology of
schizophrenia [31].
Along with its role in proline catabolism, PRODH is also known
as a key enzyme in controlling homeostasis, providing energy and
shuttling redox potential between cellular compartments and the
production of reactive oxygen species [52].
PRODH rs2904552 is a nonsynonymous mutation that causes
the substitution of an arginine for a histidine in codon 431. This
change seems to promote a functional effect, according to our in
silico findings, and also results in a moderate decrease (30–70%) of
PRODH enzyme activity [41]. Also, another study has detected
this polymorphism in combination with L441P in a subject with
high levels of proline [42]. Two other studies have investigated this
mutation; however, neither of them reported a positive association
with schizophrenia [43,53]. As we detected an association between
the major G-allele and schizophrenia, we suggest that the minor
A-allele might be a protective factor and may thus prevent the
onset of the disease by altering the enzyme activity in brain.
MRI
Our results support earlier findings of reduced total, left and
right hemisphere gray matter volumes, corpora callosa, frontal,
parietal and temporal lobes, and hippocampi, all of which are
brain regions involved in the pathophysiology of schizophrenia
[29]. We also found a significant association between the
interaction of rs2238731 and schizophrenia diagnosis with the
right pars opercularis. Controls carrying the GA genotype had an
increased volume in this region compared to GG genotype
carriers; however, patients carrying the GA genotype had a
smaller volume than did GG patients. This result should be further
verified in a larger sample due to the small sample of the GA
genotype carriers in the both the control (N = 2) and patient (N
= 19) groups.
Limitations
Some limitations of this study should be noted. First, we should
have analyzed plasma proline levels. Considering that rs2904552
variant may be affecting PRODH enzyme, its substrate might be
dysregulated. For this measurement, gender, acute alcohol use and
medication, such as valproic acid, may be taken into consideration
[43,54,55]. Furthermore, the duration of illness and medications
may have been confounding factors for the neuroimaging analysis.
Conclusions
This study represents the first report of the effects of PRODH
polymorphisms on brain morphology in both patients and healthy
controls, testing for the interaction between this SNP and a
diagnosis of schizophrenia. Only one SNP (rs2238731) seemed to
be significantly associated with right pas opercularis volume, but
this finding should be confirmed in larger samples. Therefore,
considering the functional effect of rs2904552 and the importance
of proline levels in schizophrenia, this SNP may act by altering
neurochemistry and is not responsible for the deficits in brain
structure found in schizophrenia.
In summary, this study indicates that the PRODH rs2904552
polymorphism may be a genetic risk factor for developing
schizophrenia, and further studies should address how disturbance
of the proline pathway could affect brain function.
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